mitolactol and Head-and-Neck-Neoplasms

Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mitolactol

Advanced recurrent squamous cell head and neck cancer patients were prospectively randomized to receive or not receive dibromodulcitol 10 mg/kg PO weekly for 8 consecutive weeks in addition to bleomycin chemotherapy. Patients initially entered in the study received bleomycin 15 mu/m2 three times weekly for 8 weeks. This was later changed to 15 mu/m2 twice weekly for 8 weeks because of unacceptable stomatitis. Most patients had relapsed following surgery and/or radiotherapy, but none had received prior chemotherapy. A2 : 1 randomization in favor of the dibromodulcitol-containing therapy was used. There were 12 partial responses in the 44 evaluable patients receiving the combination (27%), and 4 partial responses in the 18 patients receiving single-agent bleomycin chemotherapy (22%). This difference was not statistically significant. Response durations were also relatively short for both therapies. Within the limitations of this study, we were unable to demonstrate that patient benefit resulted from the addition of dibromodulcitol to bleomycin chemotherapy for this patient population.

Topics: Adult; Aged; Bleomycin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mitolactol

The patient was a 48-year-old male with a right subclavicular tumor. The pathological diagnosis showed primitive neuroectodermal tumor(PNET)because of the rosette formation and the positive neurogenic marker.Radiation was administered at a total dose of 50 Gy, because surgical resection would induce the loss of right arm function. CT examination demonstrated a reduction of the primary tumor and new multiple lung metastases. The patient received intravenous AI regimen(ADM and IFM). After the 7th course, both the primary tumor and multiple lung metastases decreased. AI regimen might be effective for PNET.

Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Doxorubicin; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melphalan; Middle Aged; Mitolactol; Mitomycins; Neuroectodermal Tumors, Primitive; Pyrazines; Salvage Therapy; Suicide; Tomography, X-Ray Computed

Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Mitolactol

The authors give a summarizing report about mitolactol treatments performed in Hungary. As a single-agent therapy the drug was administered in two forms: (1) every-day therapy, 5 mg/kg/day, (2) push therapy, 10 mg/kg every 5th day or 15 mg/kg every 7th day, in a total dose of 100 mg/kg in both administration forms. Out of the solid tumours the squamous cell cancers proved to be the most responsive to mitolactol therapy: first of all in tumours of the head and neck and of the lung. The study also reports the preliminary results of polychemotherapeutical protocols containing mitolactol now in progress: (1) bleomycin + mitolactol (Bristol protocol), (2) carminomycin + mitolactol and (3) adriamycin + mitolactol.

Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Leukemia, Myeloid; Mitolactol

The benefits and complications of regional chemotherapy in the treatment of head and neck tumours are discussed. Intra-arterial chemotherapy has been employed in 72 cases of preoperative, postoperative and palliative management. Cytostatic treatment consisted of combined Vincristine, bleomycin, methotrexate, and mitolactol administration by a Watkins-USCI or Sharp chronofusor. In cases of preoperative treatment the tumour regression was in the range of 50-80%. Tumours of the gingiva, parotid gland, maxilla and tonsil responded very well, tumours of the tongue less well to the treatment. The most dangerous complication is thrombosis of the common carotid artery; to avoid this complication the prothrombin index was reduced and kept at the 30-40% level.

Topics: Antineoplastic Agents; Bleomycin; Drug Therapy, Combination; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Methotrexate; Mitolactol; Vincristine

Co-operative investigation of clinical therapy for cancer is used to test hypotheses developed in single institutions and in animal research laboratories. The present studies in a large co-operative organization, the Central Oncology Group, are being conducted in seven major solid tumors in adults; in these studies patients with a poor surgical prognosis are being treated with preoperative or postoperative chemotherapy, preoperative radiotion therapy of these modalities. Results of studies currently underway or recently completed in 1,278 patients are summarized. In most instances, the research has demonstrated little or no apparent improvement in the disease free interval or the survival time from adjuvant therapy, although only on of the studies has been completed and fully evaluated thus far. In carcinoma of the colon and rectum and melanoma, mild toxicity from drug therapy has been associated with statistically significant improvement in survival times. These studies have produced base line information on disease free intervals, time to progression and survival time in patients with cancer who are seen in the participating institutions. These observations are expected to useful in the planning of future adjuvant studies.

Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Mitolactol; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Rectal Neoplasms; Vincristine